8 results about "V region" patented technology

Provided in the present invention are a genetically modified animal having a restricted humanized light chain immunoglobulin locus, a method for producing the animal, and a method for producing a common light chain antibody and an antibody library thereof using the animal. The restricted humanized light chain immunoglobulin locus comprises a portion of a V region and a portion of a J region from a light chain Kappa variable region locus of a human immunoglobulin.

The invention relates to the technical field of immunotherapy, and discloses a TCR mRNA rapid synthesis method and application thereof, a TCR double-stranded template is rapidly synthesized through two rounds of PCR amplification by adopting a mode of complementary CDR3 + J region primer + fixed fragment '5' UTR + V region 'and' C region + 3 'UTR' fragment, and then TCR mRNA is synthesized through IVT. According to the application, the reliability of the method is confirmed through first-generation sequencing, TCR specific screening is carried out by co-transforming alpha / beta double-stranded mRNA into Jurkat cells, and finally, the TCR recognition capability is further verified by co-transforming alpha / beta double-stranded mRNA into human primary T cells. The synthesis period is short, vector construction is avoided, time cost is saved, TCR synthesis flexibility is improved, and high-throughput screening of specific TCRs can be achieved in a short time.

The present disclosure provides a method for selecting hypogammaglobulinemia patients in need of immunoglobulin replacement therapy (IgG-RT) by analyzing the patient's B cell repertoire. The method can be used before treating the patient with IgG-RT. The method can also include treating the patient. Also provided herein is a diagnostic product in a computer-readable medium that provides information for patient selection. The B cell repertoire can be measured by the number or abundance of individual antibody clones, by calculating a diversity index value for antibody clones, by calculating the total frequency of the 10 to 30 most frequent antibody clones, by determining the frequency of variable region gene (V region) usage in antibody clones, by measuring the percent germline identity of V or J regions in the BCR repertoire by comparing them with corresponding germline sequences, and / or by determining the somatic mutation frequency in different regions along the V region.

The present disclosure provides a system for producing bispecific antibodies. In some embodiments, the system may comprise (a) a first library of nucleic acids, wherein the members of the first library encode a light chain fusion polypeptide comprising: (i) a common light chain comprising a light chain C region and a light chain V region; and (ii) the antigen binding region of a single chain antibody that binds to a first antigen, wherein: the sequence of the antigen binding region of the single chain antibody varies and the sequence of the common light chain does not vary; and (b) a second library of nucleic acids, wherein the members of the second library encode antibody heavy chain comprising a heavy chain V region and a heavy chain C region, where the sequence of the heavy chain V region varies. Methods of screening are also provided.

The invention discloses a bispecific antibody targeting heterogeneous macrophages, and relates to the field of biological medicines. According to the present invention, bevacizumab is adopted as a parent antibody skeleton, antibody arms targeting CD16 are arranged on the N end side, antibody arms targeting CD163 are located on the C end side, knob mutation (K322A and T366W) is introduced into the heavy chain CH3 structural domain targeting CD16, three complementary hole mutations (T366S, L368A and Y407V) are introduced into the heavy chain CH3 structural domain targeting CD163, and cysteine residues are inserted into the S354 site of the knob chain and the Y349 site of the hole chain; variable regions (V regions) targeting CD16 and CD163 are connected in series through a (G4S) 3 flexible linker and then fused with respective constant regions (C regions). The double-antibody architecture disclosed by the invention realizes collaborative optimization in structural stability, double-antigen binding specificity, macrophage targeting and functional activity, provides an efficient and safe novel candidate drug for targeted therapy of related diseases, and has important clinical transformation value and application prospect.

The invention discloses a 6G3 monoclonal antibody and application thereof, the 6G3 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the 6G3 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of VHCDR1, VHCDR2 and VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of VLCDR1, VLCDR2 and VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses a preparation method of the 6G3 monoclonal antibody. The 6G3 monoclonal antibody can neutralize SARS-CoV-2 infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

Provided herein is a DNA analysis method for DNA in an adapted library, comprising (a) contacting the DNA with (i) adapter-blocking probes and J region intron-blocking probes, thereby providing blocked DNA; and (ii) a plurality of first primers, wherein the primers bind J regions and the intron-blocking probes bind J-region introns, or the primers bind V regions and the intron-blocking probes bind V-region introns that bind V regions and / or a plurality of second primers that bind J regions; (b) extending at least a portion of the primers, wherein at least a portion of primers bound to DNA segments comprising recombined CDR3 sequences are extended across the recombined CDR3 sequences using the plurality of first primers and / or the plurality of second primers, thereby providing CDR3-enriched DNA; and (c) sequencing the CDR3-enriched DNA.

The present invention relates to animals and methods of producing antibodies. Specifically provided is a nucleic acid construct comprising a portion of a V region and a portion of a J region of a light chain Kappa variable region locus of human immunoglobulin. The nucleic acid constructs of the invention are useful in the production of antibodies or animals with limited immune light chains.